BioMark Diagnostics is an oncology-focused company developing advanced, near-to-market diagnostic technologies to improve cancer patient outcomes. Established in 2007, the company owns multiple intellectual properties for detecting and quantifying metabolites, and is backed by a global team of scientists, engineers, and medical professionals. BioMark is committed to commercializing innovative solutions that enhance the prediction and accuracy of cancer diagnoses, all while upholding the highest regulatory, clinical, and scientific standards.